Prostate-specific antigen screening: Pro - Abstract

[Guest guest]

PSA is a valid marker for prostate cancer and its aggressiveness. Level 1

evidence is now available that PSA-based screening reduces both the rate of

metastatic disease and prostate cancer-specific mortality.

Written by:

Loeb S, Catalona WJ. Are you the author?

Reference:

Curr Opin Urol. 2010 Mar 10. Epub ahead of print.

PubMed Abstract

PMID:20224413

UroToday.com Prostate Cancer Section

This article addresses something that has bothered me about the recent

debate about early detection of prostate cancer. The discussion seems to

focus exclusively on survival. Is there an advantage for men with disease

for identifying earlier to avoid or at least potentially postpone metastatic

disease?

Kathy